|
Coronary Artery Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome.
|
30596995 |
2019 |
|
Coronary Artery Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
The FAME 2 trial included patients with stable coronary artery disease involving up to 3 vessels from 28 sites in Europe and North America.
|
30840026 |
2019 |
|
Coronary Artery Disease
|
0.030 |
Biomarker
|
disease |
BEFREE |
FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) compared PCI guided by fractional flow reserve with best MT in patients with stable coronary artery disease to assess clinical outcomes and cost-effectiveness.
|
29097450 |
2018 |
|
Familial (FPAH)
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A novel pedigree with familial cortical myoclonic tremor and epilepsy (FCMTE): clinical characterization, refinement of the FCMTE2 locus, and confirmation of a founder haplotype.
|
23663087 |
2013 |
|
Familial (FPAH)
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
We provide data for a slight age-dependent progression and the presence of neuropsychiatric and neuropsychological dysfunction in this unique syndrome, for which the definition of familial or autosomal dominant cortical tremor, myoclonus, and epilepsy (FCTME/ADCME) seems to be, therefore, more appropriate.
|
21426326 |
2011 |
|
Familial (FPAH)
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
To identify the genetic locus for the familial adult myoclonic epilepsy (FAME) gene.
|
10522869 |
1999 |
|
Coronary Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The FAME 2 trial included patients with stable coronary artery disease involving up to 3 vessels from 28 sites in Europe and North America.
|
30840026 |
2019 |
|
Coronary heart disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
The FAME 2 trial included patients with stable coronary artery disease involving up to 3 vessels from 28 sites in Europe and North America.
|
30840026 |
2019 |
|
Coronary Arteriosclerosis
|
0.020 |
Biomarker
|
disease |
BEFREE |
FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) compared PCI guided by fractional flow reserve with best MT in patients with stable coronary artery disease to assess clinical outcomes and cost-effectiveness.
|
29097450 |
2018 |
|
Coronary heart disease
|
0.020 |
Biomarker
|
disease |
BEFREE |
FAME 2 trial (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) compared PCI guided by fractional flow reserve with best MT in patients with stable coronary artery disease to assess clinical outcomes and cost-effectiveness.
|
29097450 |
2018 |
|
Diabetic macular edema
|
0.020 |
Biomarker
|
disease |
BEFREE |
FAME study results are broadly supported by real-world studies in patients with chronic DME considered insufficiently responsive to available therapies.
|
28283896 |
2017 |
|
Diabetic macular edema
|
0.020 |
Biomarker
|
disease |
BEFREE |
FAME trial program results are confirmed by a series of real-world studies in eyes with chronic/recalcitrant DME.
|
28764565 |
2017 |
|
Epilepsy
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
We provide data for a slight age-dependent progression and the presence of neuropsychiatric and neuropsychological dysfunction in this unique syndrome, for which the definition of familial or autosomal dominant cortical tremor, myoclonus, and epilepsy (FCTME/ADCME) seems to be, therefore, more appropriate.
|
21426326 |
2011 |
|
Epilepsy
|
0.020 |
Biomarker
|
disease |
BEFREE |
Benign adult familial myoclonic epilepsy (BAFME or FAME) is an autosomal dominant condition, characterized by shivering-like tremors of cortical origin, myoclonus, and epilepsy.
|
18231815 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Based on such preclinical evidence, the phase II FAME trial was designed to test the hypothesis that the addition of metformin, with or without cyclic FMD, to standard platinum-based chemotherapy improves the progression-free survival of patients with advanced, LKB-1 inactive lung adenocarcinoma.
|
30617039 |
2019 |
|
Acute Coronary Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
FAME 2 enrolled patients with stable coronary artery disease (CAD), while the other two focused on non-culprit lesions in stabilized patients after acute coronary syndrome.
|
30596995 |
2019 |
|
EPILEPSY, MYOCLONIC, BENIGN ADULT FAMILIAL, TYPE 2
|
0.010 |
Biomarker
|
disease |
BEFREE |
We performed a systematic review and meta-analysis of individual patient data (IPD) of the three available randomized trials of contemporary FFR-guided PCI vs. medical therapy for patients with stable coronary lesions: FAME 2 (NCT01132495), DANAMI-3-PRIMULTI (NCT01960933), and Compare-Acute (NCT01399736).
|
30596995 |
2019 |
|
Myocardial Infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Among 441 patients in the FAME II (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation II) trial with FFR ≤0.80 who were randomized to medical therapy alone, 34 (8%) had subsequent MI within 3 years.
|
30309470 |
2018 |
|
Aortic Aneurysm, Abdominal
|
0.010 |
Biomarker
|
disease |
BEFREE |
Randomized Placebo-Controlled Trial Assessing the Effect of 24-Week Fenofibrate Therapy on Circulating Markers of Abdominal Aortic Aneurysm: Outcomes From the FAME -2 Trial.
|
30371299 |
2018 |
|
Intraocular pressure disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Mean CSFT reduced from 451.2 to 355.5 μm.ConclusionsWhile overall IOP-related emergent events were observed in similar frequency to FAME, no adverse events were seen in the subgroup with prior steroid exposure and no prior IOP events.
|
28737758 |
2017 |
|
Chronic Kidney Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
Thirty-seven component FAME Mix and sera from CKD patients were used to optimize chromatographic conditions and to select the most appropriate column.
|
28493452 |
2017 |
|
Benign adult familial myoclonic epilepsy
|
0.010 |
Biomarker
|
disease |
BEFREE |
Benign adult familial myoclonic epilepsy (BAFME or FAME) is an autosomal dominant condition, characterized by shivering-like tremors of cortical origin, myoclonus, and epilepsy.
|
18231815 |
2008 |